Efficacy and Tolerability of the APD Treatment in PAED Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0+
SponsorFresenius Medical Care Deutschland GmbH

About this trial

The Silencia PD (peritoneal dialysis) cycler offers a pediatric (PAED) mode with advanced features such as Time and Volume Optimization (TAVO), supporting precise and individualized treatment. This study evaluates the efficacy and tolerability of Automated Peritoneal Dialysis (APD) using the Silencia PD cycler in patients weighing ≤ 20 kg and able to tolerate a minimum inflow volume of 100 mL. The primary objective is to determine whether patients achieve a total weekly Kt/Vurea ≥ 1.8.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Informed consent signed and dated by legal representative and investigator/authorized physician

The minors have received the information referred to in Article 63(2) MDR in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children

The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator

patients with renal failure treated or planned to be treated with APD

Disqualifiers

Any conditions which could interfere with the patient's ability to comply with the study

Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations

Participation in an interventional clinical study during the preceding 30 days

Previous participation in the same study

Trial design

Design model

Single group

Treatments tested in this trial

  • Treatment with the pedriatic mode of the APD cycler

    Device

    Patients weighing less than 20 kg will be treated for 4 weeks with APD using the PAED mode of the Silencia PD cycler

Treatment groups

13 Participants
are divided into 1 treatment group
Group A: SilenciaPAEDExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Total weekly Kt/V urea

The primary objective is to determine whether patients achieve a total weekly Kt/V urea ≥ 1.8.

Time frame
The primary endpoint is total Kt/Vurea at week 2 and 4

Secondary outcomes

1

Mean daily ultrafiltration (UF)

Time frame
Mean UF will be measured at weeks 2 and 4
2

Residual renal function (RRF)

Renal urea clearance

Time frame
RRF will be measured at weeks 2 and 4
3

Residual renal function (RRF)

Renal creatinine clearance

Time frame
RRF will be measured at weeks 2 and 4
4

Residual renal function (RRF)

24h urine output

Time frame
RRF will be measured at weeks 2 and 4

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: